Literature DB >> 7758884

The relationship of urinary albumin excretion rate to ambulatory blood pressure and erythrocyte sodium-lithium countertransport in NIDDM.

J H Pinkney1, W J Foyle, A E Denver, V Mohamed-Ali, S McKinlay, J S Yudkin.   

Abstract

Increased erythrocyte sodium-lithium countertransport rate is found in non-diabetic subjects with essential hypertension, and in insulin-dependent diabetic subjects with nephropathy. However, relationships between these variables in non-insulin-dependent diabetic subjects are ill-defined. In order to characterise the relationships between blood pressure, urinary albumin excretion, and erythrocyte sodium-lithium countertransport, 66 subjects with non-insulin-dependent diabetes were studied. Urinary albumin excretion rate correlated with mean 24-h ambulatory systolic blood pressure (r = 0.57; p < 0.001), but not with sodium-lithium countertransport (r = 0.06; p = 0.31). No significant relationship was observed between 24-h systolic blood pressure and erythrocyte sodium-lithium countertransport (r = 0.16; p = 0.17). The principal differences between microalbuminuric and normoalbuminuric subjects (albumin excretion rate > 15 micrograms.min-1 [n = 20], and < 15 micrograms.min-1, [n = 46]) were: higher 24-h systolic blood pressure (145.9 [16.8] mmHg vs 131.9 [16.8] mmHg; p = 0.006), nocturnal heart rate (72.4 [8.9] vs 67.4 [8.9] beats.min-1; p = 0.042), and HbA1 (11.3 [1.5]% vs 10.1 [2.0]%; p = 0.028), and a longer median duration of diabetes (10.0 vs 5.0 years; p = 0.02). In contrast, there was no significant difference in sodium-lithium countertransport rate between microalbuminuric (0.41 [0.18] mmol.l-1.h-1) and normoalbuminuric subjects (0.39 [0.15] mmol.l-1.h-1; p = 0.687).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758884     DOI: 10.1007/BF00400642

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  30 in total

1.  Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey.

Authors:  J S Yudkin; R D Forrest; C A Jackson
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

2.  Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus.

Authors:  A S Krolewski; M Canessa; J H Warram; L M Laffel; A R Christlieb; W C Knowler; L I Rand
Journal:  N Engl J Med       Date:  1988-01-21       Impact factor: 91.245

3.  Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients.

Authors:  A Schmitz; M Vaeth
Journal:  Diabet Med       Date:  1988-03       Impact factor: 4.359

4.  Rapid, competitive enzymoimmunoassay for albumin in urine.

Authors:  J Chesham; S W Anderton; C F Kingdon
Journal:  Clin Chem       Date:  1986-04       Impact factor: 8.327

5.  Sodium-lithium countertransport activity in red cells of patients with insulin dependent diabetes and nephropathy and their parents.

Authors:  J D Walker; T Tariq; G Viberti
Journal:  BMJ       Date:  1990-09-29

6.  Red cell Na+/Li+ countertransport in non-insulin-dependent diabetics with diabetic nephropathy.

Authors:  M A Gall; P Rossing; J S Jensen; J Funder; H H Parving
Journal:  Kidney Int       Date:  1991-01       Impact factor: 10.612

7.  Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.

Authors:  W J Sobey; S F Beer; C A Carrington; P M Clark; B H Frank; I P Gray; S D Luzio; D R Owens; A E Schneider; K Siddle
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

8.  Blood pressure by 24 h ambulatory recordings in type 2 (non-insulin dependent) diabetics. Relationship to urinary albumin excretion.

Authors:  A Schmitz; M M Pedersen; K W Hansen
Journal:  Diabete Metab       Date:  1991 Mar-Apr

9.  Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria.

Authors:  S L Jones; C F Close; M B Mattock; R J Jarrett; H Keen; G C Viberti
Journal:  BMJ       Date:  1989-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.